STOK
Stoke Therapeutics Inc

1,011
Mkt Cap
$2.17B
Volume
15.00
52W High
$40.22
52W Low
$5.35
PE Ratio
57.49
STOK Fundamentals
Price
$36.48
Prev Close
$37.94
Open
$37.01
50D MA
$32.64
Beta
1.29
Avg. Volume
658,333.04
EPS (Annual)
-$1.65
P/B
6.79
Rev/Employee
$285,585.94
$383.52
Loading...
Loading...
News
all
press releases
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $174,200.00 in Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Arthur Tzianabos sold 4,355 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 33,243 Shares of Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Adrian Krainer sold 33,243 shares of the business's stock in a transaction on Tuesday, March 10th. The stock was sold at an average...
MarketBeat·10h ago
News Placeholder
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +168.87% and +3,813.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19h ago
News Placeholder
Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?
Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·2d ago
News Placeholder
Cresset Asset Management LLC Invests $771,000 in Stoke Therapeutics, Inc. $STOK
Cresset Asset Management LLC purchased a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 3rd quarter, according to the company in its most recent filing with...
MarketBeat·2d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Hits New 52-Week High - Still a Buy?
Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High - Should You Buy...
MarketBeat·3d ago
News Placeholder
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Tuesday
Stoke Therapeutics (NASDAQ:STOK) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...
MarketBeat·3d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Shares Up 6% - Still a Buy?
Stoke Therapeutics (NASDAQ:STOK) Trading 6% Higher - Here's What Happened...
MarketBeat·4d ago
News Placeholder
Vanguard Group Inc. Buys 217,616 Shares of Stoke Therapeutics, Inc. $STOK
Vanguard Group Inc. raised its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 7.4% during the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·6d ago
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?
Dianthus Therapeutics, Inc. (DNTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·8d ago
<
1
2
...
>

Latest STOK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.